AstraZeneca Gross Margin 2010-2024 | AZN

Current and historical gross margin for AstraZeneca (AZN) over the last 10 years. The current gross profit margin for AstraZeneca as of March 31, 2024 is %.
AstraZeneca Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2024-03-31 $47.61B $39.03B 81.98%
2023-12-31 $45.81B $37.54B 81.95%
2023-09-30 $45.00B $36.14B 80.31%
2023-06-30 $44.49B $34.74B 78.09%
2023-03-31 $43.84B $33.06B 75.40%
2022-12-31 $44.35B $31.96B 72.06%
2022-09-30 $45.15B $31.04B 68.74%
2022-06-30 $44.04B $29.15B 66.19%
2022-03-31 $41.49B $27.40B 66.05%
2021-12-31 $37.42B $24.98B 66.76%
2021-09-30 $32.82B $23.48B 71.55%
2021-06-30 $29.53B $22.58B 76.46%
2021-03-31 $27.58B $21.84B 79.18%
2020-12-31 $26.62B $21.32B 80.09%
2020-09-30 $25.87B $20.72B 80.09%
2020-06-30 $25.70B $20.57B 80.03%
2020-03-31 $25.25B $20.04B 79.36%
2019-12-31 $24.38B $19.46B 79.82%
2019-09-30 $24.14B $18.96B 78.54%
2019-06-30 $23.07B $18.09B 78.41%
2019-03-31 $22.40B $17.47B 77.99%
2018-12-31 $22.09B $17.15B 77.66%
2018-09-30 $21.45B $16.93B 78.91%
2018-06-30 $22.34B $17.72B 79.32%
2018-03-31 $22.24B $17.68B 79.50%
2017-12-31 $22.47B $18.15B 80.78%
2017-09-30 $22.27B $18.02B 80.91%
2017-06-30 $21.74B $17.84B 82.04%
2017-03-31 $22.29B $18.28B 81.98%
2016-12-31 $23.00B $18.88B 82.06%
2016-09-30 $23.82B $19.58B 82.22%
2016-06-30 $24.06B $19.69B 81.81%
2016-03-31 $24.77B $20.39B 82.31%
2015-12-31 $24.71B $20.06B 81.20%
2015-09-30 $25.03B $19.98B 79.84%
2015-06-30 $25.69B $20.27B 78.91%
2015-03-31 $26.14B $20.49B 78.36%
2014-12-31 $26.55B $20.71B 77.99%
2014-09-30 $26.77B $21.16B 79.03%
2014-06-30 $26.41B $20.97B 79.41%
2014-03-31 $25.88B $20.43B 78.95%
2013-12-31 $25.81B $20.55B 79.61%
2013-09-30 $26.15B $20.93B 80.04%
2013-06-30 $26.58B $21.33B 80.23%
2013-03-31 $27.01B $21.73B 80.44%
2012-12-31 $27.97B $22.58B 80.72%
2012-09-30 $29.35B $23.74B 80.89%
2012-06-30 $30.88B $24.95B 80.81%
2012-03-31 $32.65B $26.59B 81.43%
2011-12-31 $33.59B $27.57B 82.06%
2011-09-30 $33.55B $27.38B 81.60%
2011-06-30 $33.24B $27.13B 81.63%
2011-03-31 $32.99B $26.91B 81.59%
2010-12-31 $33.27B $26.88B 80.80%
2010-09-30 $33.60B $27.30B 81.26%
2010-06-30 $33.90B $27.87B 82.20%
2010-03-31 $33.68B $27.63B 82.05%
2009-12-31 $32.80B $27.03B 82.40%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $243.139B $45.811B
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $847.248B 122.45
Novo Nordisk (NVO) Denmark $631.845B 48.55
Johnson & Johnson (JNJ) United States $350.533B 13.92
Merck (MRK) United States $324.174B 58.98
AbbVie (ABBV) United States $302.599B 15.64
Novartis AG (NVS) Switzerland $214.497B 15.21
Pfizer (PFE) United States $155.321B 19.30
Sanofi (SNY) $119.456B 11.27
Innoviva (INVA) United States $1.013B 7.11